The application significance and research development of hepatitis B virus-large protein detection

doi:10.3969/j.issn.1673-8640.2014.02.023

Abstract

Abstract: Currently, the research about hepatitis B virus(HBV)-large surface protein (LP) is still in the infancy phase. The review describes the structure, function, testing technology and application prospects of HBV-LP and indicates the collaborative determination of hepatitis B serum marker (HBV-M), anti-hepatitis B virus core antibody IgM (HBcIgM), HBV DNA with HBV-LP, which can not only improve the detection rate, avoid missed diagnosis, but also offer more reliable judgment reference for the clinical diagnosis of HBV infection, replication, infection judgment and antiviral efficacy index.

Key words: Hepatitis B virus, Large surface protein, Application significance, Development prospect

CLC Number:

R446.62

LIU Jintao.. The application significance and research development of hepatitis B virus-large protein detection[J]. , 2014, 29(2): 186-190.

References

[1] Jung J, Iijima M, Yoshimoto N, et al. Efficient and rapid purification of drug- and gene-carrying bio-nanocapsules, hepatitis B virus surface antigen L particles, from Saccharomyces cerevisiae[J]. Protein Expr Purif, 2011, 78(2):149-155.
[2] Shen M, Wang S, Ge G, et al. Profiles of B and T cell immune responses elicited by different forms of the hepatitis B virus surface antigen[J]. Vaccine, 2010, 28(45):7288-7296.
[3] Yum JS, Ahn BC, Jo HJ, et al. Use of pre-S protein-containing hepatitis B virus surface antigens and a powerful adjuvant to develop an immune therapy for chronic hepatitis B virus infection[J]. Clin Vaccine Immunol, 2012, 19(2):120-127.
[4] Chua PK, Wang PY, Lin MH, et al. Reduced secretion of virions and hepatitis B virus(HBV) surface antigen of a naturally occurring HBV variant correlates with the accumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus[J].J Virol, 2005, 79(21):13483-13496.
[5] Liu H, Xu J, Zhou L, et al. Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway[J].Cancer Res, 2011, 71(24):7547-7557.
[6] Patient R, Hourioux C, Sizaret PY, et al. Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking [J]. J Virol, 2007, 81(8): 3842-3851.
[7] 温怀凯, 余坚, 李小永, 等.乙型肝炎病毒外膜大蛋白与HBV DNA的关系研究[J].浙江大学学报(医学版), 2010, 39(4):386-389.
[8] 吴正林, 庄鹏, 林汉利, 等.乙型肝炎病毒表面大蛋白检测用于筛查隐匿性HBV感染[J].中华实验和临床病毒学杂志, 2009, 23(5):381-383.
[9] 单平囡, 卢志勇, 宣国红, 等. HBV-LP检测HBV DNA复制的敏感性与特异性研究[J].中华实验和临床病毒学杂志, 2010, 24(1):68-70.
[10] 王建华, 王卫国, 马黎丽, 等.慢性乙型肝炎病毒感染者乙肝病毒大蛋白检测的临床意义[J].中国实验诊断学, 2012, 16(6):1023-1025.
[11] Lim SG, Cheng Y, Guindon S, et al. Viral quasi-species evolution during hepatitis B e antigen seroconversion [J].Gastroenterology, 2007, 133(3):951-958.
[12] Chai N, Gudima S, Chang J, et al. Immunoadhesins containing pre-S domains of hepatitis B virus large envelope protein are secreted and inhibit virus infection [J]. J Virol, 2007, 81 (10):4912-4918.
[13] 庄国华, 李宏, 张丽萍.HBV外膜大蛋白在判断HBV复制中的价值[J].检验医学, 2011, 26(7):444-446.
[14] 盛江来, 黄海军.拉米夫定抗病毒治疗的乙型肝炎患者血清乙肝大蛋白和乙肝病毒DNA监测分析[J].中国卫生检验杂志, 2010, 20(9):2240-2241.
[15] 蒋伯帅, 刘雪平, 蒲荣, 等.乙型肝炎病毒外膜大蛋白和HBV DNA血清学诊断价值[J].中国微生态学杂志, 2010, 22(2):154-157.
[16] 陈海潮, 单平囡, 许德顺.HBV-LP检测与HBV-DNA检测对乙型肝炎诊治中的互补作用[J].中华医院感染学杂志, 2012, 22(18):4051-4053.
[17] 范公忍, 李娟, 王帅, 等.乙型肝炎病毒外膜大蛋白检测对判断病毒复制的临床意义[J].检验医学, 2012, 27(2):145-147.
[18] 王立军, 孙燕, 付海平.乙肝病毒YMDD变异与乙型肝炎病毒大蛋白相关性的探讨[J].中华实验和临床病毒学杂志, 2010, 24(1):48-49.
[19] 王念跃, 张岱, 葛彦文, 等.血清乙型肝炎病毒大蛋白检测及其临床意义[J].中华实验和临床病毒学杂志, 2010, 24(5):349-351.
[20] 李利.动态监测乙型肝炎病毒大蛋白在乙肝治疗中的作用[J].公共卫生与预防医学, 2012, 23(4):27-29.
[21] 李敏, 耿全林.血清乙肝病毒大蛋白在HBeAb阳性患者中检测的意义[J].中西医结合肝病杂志, 2012, 22(3):176-177.
[22] 王宇, 杨延敏.对乙型肝炎患者检测乙肝表面抗原大蛋白和前S1抗原的区别和临床意义[J].大连医科大学学报, 2010, 32(6):706-708.
[23] 牛文强, 陈杰.乙型肝炎病毒外膜大蛋白与HBV DNA、ALT的关系及其临床意义[J].国际检验医学杂志, 2011, 32(10):1045-1046.
[24] 钟小强, 吴正林, 凌利芬, 等. HBV感染者血清表面抗原大蛋白, DANE颗粒, HBV-DNA与PreS1蛋白检测分析[J].现代检验医学杂志, 2010, 25(6):96-98.
[25] 廖洪. 172例慢性乙肝患者血清乙肝病毒外膜大蛋白检测结果分析[J].内蒙古中医药, 2012, 31(7):91-92.
[26] 王菁, 张小宁, 程晓东, 等. 乙型肝炎病毒大蛋白检测对乙型肝炎患者的临床价值探讨[J].现代检验医学杂志, 2011, 26(6):95-97.
[27] 刘鸿生, 胡志刚, 俞蕾, 等. HBeAg阴性乙型肝炎患者HBV-LP及HBV-DNA检测分析[J].中华医院感染杂志, 2012, 22(13):2743-2745.
[28] 刘素霞, 郑颖, 张瑾. HBeAg阴性乙肝患者血清乙肝病毒外膜大蛋白的检测意义[J].中国卫生检验杂志, 2010, 20(6): 1440-1441.
[29] 张静, 高纯, 史进方, 等.乙型肝炎病毒外膜大蛋白和病毒标志物联合检测的意义[J].检验医学与临床, 2012, 9(6): 646-648.
[30] 肖晋, 王立军, 蔡淑英, 等.乙型肝炎病毒表面大蛋白血清学检测及肝病间的差异性研究[J].当代医学, 2011, 17(19):34-35.
[31] 耿坤静, 杜博勋, 李永勤, 等.乙型肝炎病毒大蛋白检测在乙型肝炎抗病毒治疗中的作用[J].河北医药, 2012, 34(9): 1319-1320.
[32] 张玲, 潘虹. 慢性乙型肝炎患者血清乙型肝炎病毒e抗原及乙肝病毒载量和丙氨酸氨基转移酶的关系[J].临床医学, 2012, 32(2):46-47.
[33] 周丽英, 蒋理. 乙型肝炎病毒核酸载量与乙型肝炎病毒大蛋白的相关性研究[J].中华疾病控制杂志, 2012, 16(1): 39-42.
[34] Fan X, Fang D, Bin D, et al. Serum levels of surface large envelope proteins: prognostic markers for hepatitis B e antigen-negative patients with adefovir dipivoxil treatment[J]. Antivir Ther, 2009, 14(8):1149-1156.
[35] 温燕忠, 朱火星, 余碧雅. 孕妇血清乙肝病毒大蛋白分子在母婴传播的意义[J].中外健康文摘, 2010, 7(24):52-53.
[36] 王淑梅, 王文光, 刘广勤.孕妇乙型肝炎病毒感染与胎儿宫内感染的关系[J].中国生育健康杂志, 2009, 20(3):163-164.
[37] 潘国绍, 蒋兴祥, 陈金堃, 等.乙型肝炎病毒大蛋白用于公共卫生体检领域检测意义的研究[J].中华实验和临床病毒学杂志, 2011, 25(3):185-187.
[38] 胡云, 张培男, 钱进. 乙肝病毒外膜大蛋白及其在出国人员健康体检中的应用价值[J].中国国境卫生检疫杂志, 2010, 33(1): 22-26.
[39] Deng Q, Kong YY, Xie YH, et al. Expression and purification of the complete PreS region of hepatitis B virus [J].World J Gastroenterol, 2005, 11(20):3060-3064.
[40] Dorobantu C, Macovei A, Lazar C, et al. Cholesterol depletion of hepatoma cells impairs hepatitis B virus envelopment by altering the topology of the large envelope protein[J]. J Virol, 2011, 85(24):13373-13383.
[41] Hung JH, Yan CW, Su IJ, et al.Hepatitis B virus surface antigen interacts with acid alpha-glucosidase and alters glycogen metabolism[J]. Hepatol Res, 2010, 40(6):633-640.
[42] Lei Y, Liu H, Yang Y, et al. Interaction of LHBs with C53 promotes hepatocyte mitotic entry: a novel mechanism for HBV-induced hepatocellular carcinoma[J]. Oncol Rep, 2012, 27(1):151-159.
[43] Mun HS, Lee SA, Kim H, et al. Novel F141L pre-S2 mutation in hepatitis B virus increases the risk of hepatocellular carcinoma in patients with chronic genotype C infections[J]. J Virol, 2011, 85(1):123-132.
[44] Hung JH, Teng YN, Wang LH, et al. Induction of Bcl-2 expression by hepatitis B virus pre-S2 mutant large surface protein resistance to 5-fluorouracil treatment in Huh-7 cells[J]. PLoS One, 2011, 6(12):e28977.
[45] Xie Y, Zhai J, Deng Q, et al. Entry of hepatitis B virus: mechanism and new therapeutic target[J]. Pathol Biol (Paris), 2010, 58(4):301-307.